CYP2D6 and breast carcinoma: The results of this study suggest that CYP2D6 and CYP2C19 genotypes need to be tested in patients with breast cancer to allow physicians to tailor the treatment according to these genotypes, thereby reducing mortality rates and personalising the treatment of patients with breast cancer.